JP5528705B2 - ヒトにおける早漏を治療するための方法 - Google Patents

ヒトにおける早漏を治療するための方法 Download PDF

Info

Publication number
JP5528705B2
JP5528705B2 JP2008545930A JP2008545930A JP5528705B2 JP 5528705 B2 JP5528705 B2 JP 5528705B2 JP 2008545930 A JP2008545930 A JP 2008545930A JP 2008545930 A JP2008545930 A JP 2008545930A JP 5528705 B2 JP5528705 B2 JP 5528705B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
tramadol
acceptable salt
dextromethorphan
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008545930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519350A (ja
JP2009519350A5 (https=
Inventor
チャンドラ シング
Original Assignee
トリニティ ラボラトリーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリニティ ラボラトリーズ インコーポレイテッド filed Critical トリニティ ラボラトリーズ インコーポレイテッド
Publication of JP2009519350A publication Critical patent/JP2009519350A/ja
Publication of JP2009519350A5 publication Critical patent/JP2009519350A5/ja
Application granted granted Critical
Publication of JP5528705B2 publication Critical patent/JP5528705B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008545930A 2005-12-13 2006-12-11 ヒトにおける早漏を治療するための方法 Expired - Fee Related JP5528705B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74981305P 2005-12-13 2005-12-13
US60/749,813 2005-12-13
PCT/US2006/061873 WO2007070779A2 (en) 2005-12-13 2006-12-11 A method to treat premature ejaculation in humans

Publications (3)

Publication Number Publication Date
JP2009519350A JP2009519350A (ja) 2009-05-14
JP2009519350A5 JP2009519350A5 (https=) 2010-02-12
JP5528705B2 true JP5528705B2 (ja) 2014-06-25

Family

ID=38163598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545930A Expired - Fee Related JP5528705B2 (ja) 2005-12-13 2006-12-11 ヒトにおける早漏を治療するための方法

Country Status (5)

Country Link
US (2) US8604082B2 (https=)
EP (1) EP1969117A4 (https=)
JP (1) JP5528705B2 (https=)
MX (1) MX2008007589A (https=)
WO (1) WO2007070779A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5528705B2 (ja) 2005-12-13 2014-06-25 トリニティ ラボラトリーズ インコーポレイテッド ヒトにおける早漏を治療するための方法
CN101657101B (zh) * 2007-02-12 2013-12-11 Dmi生物科学公司 并存早泄和勃起功能障碍的治疗
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
WO2009021058A2 (en) * 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CN101716162B (zh) * 2009-11-26 2012-11-14 扬州中宝制药有限公司 一种氨茶碱缓释胶囊及其制备方法
AU2011223807B2 (en) * 2010-03-02 2016-05-12 Fervent Pharmaceuticals, Llc Methods and compositions for treating or preventing symptoms of hormonal variations
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
WO2014028796A2 (en) * 2012-08-17 2014-02-20 Smartek International Llc Preparation of desiccated liposomes for use in compressible delivery systems
US20150250791A1 (en) * 2014-03-06 2015-09-10 Bhaskara Rao Jasti Combining sildenafil with caffeine in an oral disintegrating dosage form
WO2015134695A1 (en) * 2014-03-07 2015-09-11 Vyrix Pharmaceuticals, Inc. Method of mitigating the side effects of a phosphodiesterase type v inhibitor in a subject
WO2017017511A1 (en) * 2015-07-28 2017-02-02 Kameel Selim Modified release formulation for treating premature ejaculation
US10888552B2 (en) * 2016-08-12 2021-01-12 Steven Rothman Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
WO2020006606A1 (en) * 2018-07-05 2020-01-09 Helium 3 Resources Pty Ltd A pharmaceutical composition and method of use of same
CN108836943A (zh) * 2018-07-24 2018-11-20 江苏金丝利药业股份有限公司 一种注射用氢溴酸右美沙芬及其制备方法
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4507323A (en) 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5327910A (en) 1989-06-29 1994-07-12 S & T No 27 Pty Ltd Therapeutic device for male sexual dysfunction
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US5063915A (en) 1989-12-18 1991-11-12 Wyckoff Robert L Male genital device and method for control of ejaculation
WO1996032952A1 (en) 1995-04-21 1996-10-24 Oswald Edmonds Hooper Caffeine composition as medicament and use thereof
US5151448A (en) 1991-07-12 1992-09-29 Crenshaw Roger T Method for treating premature ejaculation
US5535758A (en) 1992-10-13 1996-07-16 Hagihara; Hideo Aiding device for men with sexual dysfunction
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
IT1264965B1 (it) 1993-11-12 1996-10-17 Giorgio Cavallini Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ZA945452B (en) 1994-01-24 1996-01-25 Ernest Keith Shooter Device for assisting erection
JP4097285B2 (ja) 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037360A (en) 1997-10-28 2000-03-14 Vivus, Incorporated Administration of 5-HT3 receptor antagonists to treat premature ejaculation
EP1397126B9 (en) * 2001-03-16 2007-02-21 DMI Biosciences, Inc. Use of tramadol for delaying ejaculation
US6794387B2 (en) 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds
AU2003291302A1 (en) * 2002-11-06 2004-06-03 Azaya Therapeutics, Inc. Method for treatment of premature ejaculation in humans
US20050113294A1 (en) 2003-11-21 2005-05-26 Adolor Corporation. Carboxamide and amino derivatives and methods of their use
MXPA06011891A (es) * 2004-04-20 2007-04-24 Pfizer Metodo para tratar el dolor neuropatico.
US20080176873A1 (en) 2004-11-10 2008-07-24 Trinity Laboratories, Inc. Novel Pharmaceutical Compositions for Treating Acquired Chronic Pain and Associated Dysphoria
JP5528705B2 (ja) 2005-12-13 2014-06-25 トリニティ ラボラトリーズ インコーポレイテッド ヒトにおける早漏を治療するための方法
US7645767B2 (en) 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2008131256A1 (en) 2007-04-19 2008-10-30 Trinity Laboratories Inc. Improved treatments for premature ejaculation in humans
WO2009021058A2 (en) 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy

Also Published As

Publication number Publication date
WO2007070779A2 (en) 2007-06-21
JP2009519350A (ja) 2009-05-14
MX2008007589A (es) 2009-01-27
US20140296262A1 (en) 2014-10-02
US8604082B2 (en) 2013-12-10
EP1969117A4 (en) 2008-12-17
US20090215810A1 (en) 2009-08-27
EP1969117A2 (en) 2008-09-17
WO2007070779A3 (en) 2007-12-13
US9272037B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
US9272037B2 (en) Method to treat premature ejaculation in humans
US8877755B2 (en) Dopamine-agonist combination therapy for improving sleep quality
US8729070B2 (en) CNS pharmaceutical compositions and methods of use
CA2716080C (en) Cns pharmaceutical compositions and methods of use
US20020019421A1 (en) Compositions and therapy for substance addiction
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
US20100267735A1 (en) Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
US9238033B2 (en) Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
AU749703B2 (en) Combination therapy for modulating the human sexual response
US20100120780A1 (en) Treatments for premature ejaculation in humans
US7754767B2 (en) Method for treatment of premature ejaculation in humans
WO2016027259A1 (en) Cns pharmaceutical compositions and methods of use
US20020168403A1 (en) Compositions and therapy for substance addiction
JPH1129476A (ja) 麻薬依存抑制剤
TW574037B (en) Nicotine addiction treatment
WO2026068950A1 (en) Pharmaceutical compositions of 5-meo-dmt for use in the treatment of alcohol use disorders
KR20240167886A (ko) 산후 우울증의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
WO2002011729A1 (en) Novel compositions and methods for treatment of male erectile dysfunction
CN104619323A (zh) 用于在治疗性功能障碍中使用的a3腺苷受体配体
KR20050016679A (ko) 금연을 촉진시키는 방법
HK1128226B (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction
HK1209342B (en) A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
HK1128226A1 (en) Pharmaceutical combinations comprising testosterone in the treatment of female sexual dysfunction

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120704

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121009

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121023

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20121026

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130619

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130820

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140416

R150 Certificate of patent or registration of utility model

Ref document number: 5528705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees